Indaptus Therapeutics is trading at $2.15 (-10.04%) amid broader market pressure following hotter-than-expected headline CPI and weakness in biotech stocks. - No fresh company announcement was identified for October 14; recent company news listings show earlier releases. - Supplied market context shows the S&P 500 down 0.61%, Nasdaq down 0.91%, and XBI down 2.01%. - The delayed private-placement closing is prior context, not a confirmed new catalyst for this session.